| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |